The effect of TRAIL on the expression of multidrug resistant genes MDR1, LRP and GST-π in drug-resistant gastric cancer cell SGC7901/VCR

Hepato-Gastroenterology

Volumn 59, Issue 120, 2012, Pages 2672-2676

  Zhang, Kai Guang ^a,b   Qin, Cheng Yong ^a   Wang, Hui Qun ^b   Wang, Jun Xian ^b   Wang, Qiao Min ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Gastric carcinoma; Glutathione S transferase ; Lung resistance protein; Multidrug gene 1; TRAIL

Indexed keywords

GLUTATHIONE TRANSFERASE P1; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE;

ARTICLE; CANCER CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VAULT RIBONUCLEOPROTEIN PARTICLES; VINCRISTINE;

EID: 84872083997     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11850     Document Type: Article

References (31)

1. Sun X, Mu R, Zhou Y, et al.: Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Chin J Oncol 2004; 26(1):4-9.
2. Tozawa K, Oshima T, Kobayashi T, et al.: Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Anticancer Res 2008; 28(4B):2087-2092.
3. Shi LX, Ma R, Lu R, et al.: Reversal effect of tyroservatide (YSV) tripeptide on multidrug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. Cancer Lett 2008; 269(1):101-110.
4. Song X, Wang JB, Yin DL, et al.: Down-regulation of lung resistance related protein by RNA interference targeting surviving induces the reversal of chemoresistances in hepatocellular carcinoma. Chin Med J (Engl) 2009; 122(21):2636-2642.
5. Hao Y, He Z, Du N, et al.: Suppression of MDR1 gene expression and reversal of cisplatin resistance in renal carcinoma cells by RNA interference. Tumor 2010; 30(2):115-118.
6. Zhang D, Fan D: Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007; 7(10):1369-1378.
7. Yu DQ, Yi YF: Expression and significance of MRP, GST π, TopoIIα, and LRP in gastric carcinoma. Chin J Cancer 2003; 22(5):496-499.
8. Chen WY, Mao WM, Zhao L, et al.: Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance. Chin J Oncol 2005; 27(12):738-740.
9. Wang I, Zhang K, Wang Q, et al.: Significance of expression of cyclooxygenase-2 and Lung resistance protein in gastric cancer. World Chin J Digestol 2009; 17(22):2312-2316.
10. Wideroff L, Vaughan TL, Farin FM, et al.: GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev 2007; 31(3):233-236.
11. Illmer T, Schaich M, Platzbecker U, et al.: P-glycoprotein mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18(3);401-408.
12. Szakács G, Paterson JK, Ludwig JA, et al.: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5(3):219-234.
13. Li X, Li JP, Yuan HY, et al.: Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol 2007; 29:607-617.
14. Scheper RJ, Broxterman HJ, Scheffer GL, et al.: Over expression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53:1475-1479.
15. Xie H, Xu X, Ke M, et al.: A study on the expression of multidrug resistance-associated protein genes in lung cancer tissues and other malignant tumor. Practical J Cancer 2010; 25(2):150.
16. Fojo T, Bates S: Strategies for reversing drug resistance. Oncogene 2003; 22:7512-7523.
17. Kwon HC, Roh MS, Oh SY, et al.: Prognostic value of expression of ERCC1, thymidylate synthase and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18(3):504-509.
18. Schaefer U, Voloshanenko O, Willen D, Walczak H: TRAIL: A multifunctional cytokine. Front Biosci 2007; 12:3813-3824.
19. Cretney E, Takeda K, Smyth MJ: Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 2007; 39(2):280-286.
20. Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett 2009; 285(1):1-5.
21. Su YX, Wang L: Effect of combination of TRAIL and paclitaxel on human gastric cancer cell line SGC7901(J). China Oncol 2008; 18(4):262-266.
22. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S: Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001; 81(3):380-390.
23. Abdulghani J, El-Deiry WS: TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010; 14(10):1091-1108.
24. Liu FT, Agrawal SG, Gribben JG, et al.: Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008; 111(5):2797-2805.
25. Shenoy K, Wu Y, Pervaiz S: LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and upregulation of death receptors. Cancer Res 2009; 69(5):1941-1950.
26. Komdeur R, Plaat BE, Hoekstra HJ, et al.: Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor related apoptosis inducing ligand-alpha and melphalan. Cancer 2001; 91(10):1940-1948.
27. Wang Q, Chen XP, Hai S, et al: TNF-alpha induced reversal of multidrug resistance in human hepatocellular carcinoma cells. Zhonghua Wai Ke Za Zhi 2007; 45(9):602-604.
28. Wu Y, Fan Y, Xue B, et al.: Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene 2006; 25(42):5787-5800.
29. Seo SB, Hur JG, Kim MJ, et al.: TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol Cancer 2010; 9:199-212.
30. Zhu G, Qu Q, Chen Q, et al.: Expression and significance of DR5, DcRl protein for TNF-related apoptosis-inducing ligand and P-glycoprotein in endometrial carcinoma. J Shanxi Medical University 2006; 37(8):800-803.
31. Liu L, Fei S: An experimental study of the effect of TRAIL combined with PDTC on the growth inhibition and apoptosis induction of SGC-7901gastric cancer cells. Acta Academiae Medicinae Xuzhou 2009; 29(11):718-721.